147695-92-9

Usage

Uses

Used in Pharmaceutical Industry:
N-(4-PHENYLSULFONYLPHENYL)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANAMIDE is used as a KIR channel opener for its ability to modulate the activity of Kir6, KATP channels. This modulation can be beneficial in the treatment of various conditions related to the dysfunction of these channels, such as certain types of diabetes and cardiovascular diseases.
Used in Research Applications:
In the field of research, N-(4-PHENYLSULFONYLPHENYL)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANAMIDE serves as a valuable tool for studying the function and regulation of KIR channels. Its potent and selective action on these channels allows researchers to investigate the underlying mechanisms of channel activity and its impact on cellular processes.
Used in Drug Development:
The compound's ability to modulate KIR channels without exhibiting antiandrogen properties makes it a promising candidate for the development of new therapeutic agents. Researchers and pharmaceutical companies can utilize N-(4-PHENYLSULFONYLPHENYL)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANAMIDE as a starting point for designing novel drugs that target KIR channels for the treatment of various diseases and conditions.

InChI:InChI=1/C16H14F3NO4S/c1-15(22,16(17,18)19)14(21)20-11-7-9-13(10-8-11)25(23,24)12-5-3-2-4-6-12/h2-10,22H,1H3,(H,20,21)

Upstream product

• 374-35-6 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid 
• 7019-01-4 p-aminophenyl phenyl sulfone 
• 243869-56-9 R/S-3,3,3-trifluoro-2-hydroxy-2-methylproanoyl chloride 

Relevant academic research and scientific papers

N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: K(ATP) potassium channel openers. Modifications on the western region

A subset of antiandrogen compounds, the N-aryl-3,3,3-trifluoro-2- hydroxy-2-methylpropanamides 1, were found to activate ATP sensitive potassium channels (K(ATP)) and represent a new class of potassium channel openers (PCOs). A structure-activity relation

Therapeutic alcohols

Compounds of formula I STR1 wherein X, A, B, R1 and R2 have the meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable in vivo hydrolysable ester thereof, processes for preparing the compounds and pharmaceutical compositions comprising them. The compounds are useful as potassium channel openers and as therapeutic agents in the treatment of urinary incontinence.

Therapeutic amides

Amides having formula I: STR1 wherein E, X, R2 and R3 have the meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable in vivo hydrolysable esters thereof, which are useful in the treatment of urinary incontinence. Further provided are processes for preparing the amides and pharmaceutical compositions containing them.